Active anti-HIV compounds will likely be used in combination with other anti-HIV agents or with agents that inhibit opportunistic agents. Thus, it is critical to evaluate the activity of the compound in combination with agents being used in the treatment of AIDS patients. We routinely evaluate the interaction of compounds with other anti-HIV compounds including nucleoside RT inhibitors (AZT, ddI, ddC, d4T and 3TC), nonnucleoside RT inhibitors (a -APA, TSAO, costatolide, TIBO, UC10), protease inhibitors (indinavir, saquinavir, KNI 272) attachment inhibitors (sulfated polysaccharides, sulfonated dyes) and neutralizing antibodies. Data are evaluated using multiple statistical software packages including the Prichard and Shipman MacSynergy II, the Chou and Talalay median dose effect equation and ComboSTAT. The interactions of the compounds are evaluated in terms of efficacy (synergy, additivity, antagonism) and toxicity (combination toxicity). Compounds can be tested in two (2) or three (3) drug combinations with investigatory and clinically relevant agents.
Anti-HIV Evaluation
Confirmatory HIV Assays
Secondary Biological Assays
Topical Microbicide Program
Combination Assays
Contact Us:
Phone: 888-322-1166
Email: busdev@southernresearch.org